Evaluation of transabdominal ultrasound after oral administration of an echoic cellulose-based gastric ultrasound contrast agent for gastric cancer

Zhijun Liu¹, Jintao Guo², Shupeng Wang², Ying Zhao³, Jing Li¹, Weidong Ren¹, Shaoshan Tang¹, Limei Xie¹, Ying Huang¹, Siyu Sun² and Liping Huang¹*

Abstract

Background: With the remarkable improvements in ultrasound equipment, transabdominal ultrasound after oral administration of an echoic cellulose-based gastric ultrasound contrast agent (TUS-OCCA) has recently been suggested to be effective in initial screening of gastric cancer. The aim of this study was to evaluate the diagnostic value of TUS-OCCA for gastric cancer.

Methods: Consecutive patients with gastric cancers who underwent resection in our hospital were enrolled. Before the lesion was resected, TUS-OCCA examination was performed by a skilled examiner who was blinded to the site, size, and endoscopy diagnosis of the lesion. TUS-OCCA findings were compared with those of endoscopy and pathological diagnoses as the gold standard.

Results: There were a total of 288 consecutive patients enrolled in the study, including 228 with advanced gastric cancers (T2–T4 stage), 50 with early gastric cancer (26 with stage T1b and 24 with stage T1a), and 10 with high-grade intraepithelial neoplasia. TUS-OCCA had a detection rate of 100% (228/228) for advanced gastric cancers, 77% (20/26) for stage T1b, 67% (16/24) for stage T1a, and 60% (6/10) for high-grade intraepithelial neoplasia. The majority of patients with undetectable neoplasms using TUS-OCCA were obese (body mass index, 28.7–31.8 kg/m²). The overall accuracy of TUS-OCCA in determining the T stage of gastric cancer was 77.3% (62.5% for T1a, 70% for T1b, 71.1% for T2, 85.2% for T3, and 73.3% for T4).

Conclusions: These findings indicate that TUS-OCCA achieved a high detection rate for gastric cancers and was useful in assessing the degree of gastric cancer invasion.

Keywords: Cellulose-based ultrasound contrast agent, Detection rate, Gastric cancer, Initial screening, Transabdominal ultrasound

Background

Gastric cancer is the fourth most common cancer and the second leading cause of cancer-related death worldwide [1–3]. The use of gastroscopy for opportunistic screening of gastric cancers is widely accepted; however, the employment of this procedure for mass screening of gastric cancers remains questionable, even in developed countries such as Japan [1–3]. Therefore, the barium swallow test continues to be the most common mass screening tool for gastric cancers in Japan and Korea [1–3]. However, a simple, economic, efficient, and non-invasive approach for mass screening of gastric lesions would be welcome.

Transabdominal ultrasound is increasingly used for the detection and evaluation of gastrointestinal lesions [4–11]. However, the diagnostic value of transabdominal ultrasound after oral administration of an echoic cellulose-based gastric ultrasound contrast agent (TUS-OCCA) has recently been suggested to be effective in initial screening of gastric cancer.
based gastric ultrasound contrast agent (TUS-OCCA) for
gastric cancer remains unclear. The purpose of this study
was to evaluate the diagnostic value of TUS-OCCA for
this disease.

Methods

Permission
The study protocol was approved by the Ethics Commit-
tee of Sheng Jing Hospital, China Medical University
(Liaoning, China), and informed consent was obtained
from all patients prior to enrollment.

Patients
From May 1, 2012 to June 1, 2015, consecutive patients
who underwent resection in our hospital for gastric cancer
and high-grade intraepithelial neoplasia were prospect-
ively enrolled in this study. All of the enrolled subjects
underwent an endoscopic examination and biopsy in our
hospital or an affiliated facility approximately 1 week be-
fore surgery. For subgroup analysis, the enrolled patients
were classified into two groups according to body habitus:
Group S (suitable body habitus) and Group U (unsuitable
body habitus). Group S included patients considered suit-
able for TUS-OCCA (visualization of the cardia and pyl-
orus, as shown in Fig. 1a and b), while Group U included
patients deemed less suitable for TUS-OCCA (inability to
visualize the cardia or pylorus, as shown in Fig. 1c and d).
The body habitus characteristics of the enrolled patients
were evaluated using conventional transabdominal ultra-
sound before oral administration of contrast agent. The
patients were subsequently classified into Groups S and U
before TUS-OCCA examination was performed.

TUS-OCCA examination
All TUS-OCCA examinations were performed before le-
sion resection by an investigator with 5 years of experience
(ZJL) who was blinded to the site, size, and endoscopic
diagnosis of the lesion; however, he was aware of the pres-
ence of gastric lesions scheduled to be resected surgically
or endoscopically. Sonographic examinations were per-
formed using the Toshiba Aplio 400 (Toshiba Medical Sys-
tems Corporation, Tokyo, Japan), Hitachi 8500 (Hitachi,
Ltd., Tokyo, Japan), or IU22 (Philips Healthcare, Bothell,
WA, USA) systems with a 2–5 MHz convex array probe.

Fig. 1 Definition of Groups S and U. a Visualization of the cardia (arrows) between the liver and aorta is acceptable. b Visualization of the pylorus (arrows) between the liver and pancreas is also acceptable. c The cardia between the liver and aorta is not acceptably visualized. d The pylorus between the liver and pancreas is not acceptably visualized. Visualization of the cardia and pylorus is acceptable in Group S, but not in Group U. An, antrum; P-head, pancreatic head.
Cellulose-based oral contrast agent
The ultrasound contrast agent used was the World instant gastrointestinal ultrasound agent (Huzhou East Medical Devices, Huzhou, Zhejiang, China). It was reconstituted in 500 mL of boiling water, which formed a homogeneous thin paste. This was cooled to a suitable temperature and then administered orally to improve stomach distension. The uniform thin paste formed by this cellulose-based contrast agent reportedly had a pleasant taste (slightly sweet) and was well tolerated by most patients. TUS-OCCA examination was performed at approximately 1 min after the contrast agent was swallowed by the patient. The acoustic velocity and specific acoustic impedance of the contrast agent were similar to those of liver tissue. The stomach, once filled with the cellulose-based ultrasound contrast agent, appeared as a homogeneous mid- to high-level echogenicity. No antispasmodics were used.

Stomach scanning procedure
The whole stomach was scanned in five views as follows (Fig. 2): (1) mainly the gastric cardia (Fig. 2a and b) and then the gastric fundus (Fig. 2c), which was performed by moving the probe from the xiphoid process to the left costal arch, with the subject in the supine position; (2) mainly the gastric fundus (Fig. 2d), which was performed by placing the probe at the location of the left intercostal space; (3) the gastric fundus, body, and antrum in a transverse section (Fig. 2e–h), which was performed by moving the probe from the left costal arch to the right costal arch, with the subject lying in the right decubitus position; (4) the gastric fundus, body, and antrum in a coronal section (Fig. 2i–k), which was performed by rotating the probe along the left costal arch, while using the caudal end of the probe as an axis (simultaneously tilting the probe at ~45°) with the subject lying in the right decubitus position; and (5) the gastric antrum (Fig. 2l), which was performed by placing the probe vertically to the right costal arch, with the subject lying in the supine position. Views 3 (Fig. 2e–h) and 4 (Fig. 2i–k) were key to obtaining serial transverse and coronal sections, respectively, of the whole stomach including the gastric fundus, body, angle, and antrum.

Sonographic criteria
The sonographic criteria for the diagnosis of stomach neoplasms were based on recommendations in the literature.

![Fig. 2 Normal sections of the contrast-filled whole stomach obtained in five views: (1) sagittal section of the a lower esophagus (white arrow), b gastric cardia (white arrow), and c oblique section of the gastric fundus (cardia; white arrow); (2) d transverse section of the gastric fundus; (3) serial transverse sections of e gastric fundus, f body, g angle, and h antrum (black arrow; transverse section of the gastric angle); (4) serial coronal sections of i gastric fundus, j body, k angle and antrum (black arrow; coronal section of the gastric angle); and (5) l longitudinal section of the gastric antrum. P, pancreas](https://example.com/fig2.png)
and our previous experience. Gastric high-grade intraepithelial neoplasia and intramucosal (stage T1a) early gastric cancer presented on ultrasonograph scans as hypoechoic thickening of the mucosal layer, with the hyperechoic submucosal layer intact. Early gastric cancer involving the submucosal layer (stage T1b) presented as hypoechoic thickening of the mucosal and submucosal layers, with the hypoechoic muscularis propria layer intact. Advanced gastric cancers (stage T2–T4) presented as hypoechoic thickening of the gastric wall with disruption to the muscularis propria layer. Features, such as tumor size, site, and echo pattern, were recorded during each TUS-OCCA examination and the findings were compared with those of endoscopic and pathological diagnoses.

All statistical analyses were performed using the Fisher’s exact test with SPSS statistical software (version 21.0; IBM-SPSS, Inc., Chicago, IL, USA). A probability (p) value < 0.05 was considered statistically significant.

Results
A total of 288 patients (178 men and 110 women; mean age, 54.6 years; age range, 32–83 years) who underwent treatment for gastric cancer and high-grade intraepithelial neoplasia were enrolled. Patients included 228 with advanced gastric cancers (stage T2–T4), 50 with early gastric cancers (26 with stage T1b and 24 with stage T1a), and 10 with high-grade intraepithelial neoplasia. According to the habitus characteristics evaluated using transabdominal ultrasound, 184 (64 %) patients were classified into Group S and 104 (36 %) into Group U.

As shown in Table 1, TUS-OCCA achieved a detection rate of 100 % (228/228) for advanced gastric cancers, 77 % (20/26) for stage T1b early gastric cancer, 67 % (16/24) for stage T1a early gastric cancer, and 60 % (6/10) for high-grade intraepithelial neoplasia. Subgroup analysis of the detection rates for TUS-OCCA in the patients within Group S (146 patients with advanced gastric cancer, 32 patients with early gastric cancer, and 6 with high-grade intraepithelial neoplasia) was 100 % (184/184). The detection rates for TUS-OCCA in the patients in Group U were 83 % (86/104) (including 100 % (82/82) for advanced gastric cancers, 18 % (4/22) for early gastric cancer and high-grade intraepithelial neoplasia). The 14 patients with early gastric cancer and four with high-grade intraepithelial neoplasia who were undetected using TUS-OCCA examination were in Group U. The difference in the detection rates between Groups S and U (100 % vs. 83 %) was statistically significant (p < 0.05, Fisher’s exact test).

Subgroup analysis data regarding the detection rates using TUS-OCCA evaluated according to the location of the lesions are detailed in Table 2. For lesions located in the antrum, the detection rate was 95 % (87/92); for lesions located in the angle, the detection rate was 96 % (70/73); for lesions located in the body, the detection rate was 97 % (38/39); for lesions located in the fundus, the detection rate was 63 % (5/8); and for lesions located in the cardia, the detection rate was 92 % (70/76).

As detailed in Table 3, the overall accuracy of TUS-OCCA in determining the T stage of gastric cancer was 77.3 % (62.5 % for T1a, 70 % for T1b, 71.1 % for T2, 85.2 % for T3, and 73.3 % for T4). Figures 3 and 4 show examples of early and advanced gastric cancers, respectively on TUS-OCCA images.

Discussion
Because gastric cancer is the second leading cause of cancer-related death worldwide, it is important in terms of the further development of anticancer strategies [14–16]. The 5-year survival rate for gastric cancers at stages IA, IB, II, IIIA, IIIB, and IV are reportedly 92.2, 85.3, 72.1, 52.8, 31.0, and 14.9 %, respectively [17]. Hence, earlier detection of gastric cancers will enable better prognosis.

Various imaging modalities are used to detect gastric lesions, including endoscopy, barium studies, computed tomography, magnetic resonance imaging, and ultrasound [18–21]. Nevertheless, to date, no suitable mass screening tool for gastric cancer has been recommended by the World Health Organization; hence, there is a need for a method that is relatively safe, simple, inexpensive, and reliable [22]. Gastroscopy appears to be the most accurate method for the detection of gastric lesions; however, patient discomfort, risk of cross-infection, the high cost of screening, and the lack of experienced endoscopists hamper its application. Therefore, barium swallow continues

| Table 1 Detection rates for gastric cancer and high-grade intraepithelial neoplasia using TUS-OCCA | Detection rates | Total |
|---|---|---|
| Group S | Group U | |
| **Gastric cancer and premalignant lesions** | | |
| High grade intraepithelial neoplasia | 6/6 | 0/4 | 6/10 (60 %) |
| Stage T1a early gastric cancer | 14/14 | 2/10 | 16/24 (67 %) |
| Stage T1b early gastric cancer | 18/18 | 2/8 | 20/26 (77 %) |
| Advanced gastric cancer (stage T2 ~ T4) | 146/146 | 82/82 | 228/228 (100 %) |
| **Total** | 184/184 (100 %) | 86/104 (83 %) | 270/288 (94 %) |

TUS-OCCA, transabdominal ultrasound after oral administration of an echoic cellulose-based contrast agent. The difference in the detection rates between Groups S and U (100 % vs. 83 %) was significant (p < 0.05, Fisher’s exact test)
Table 2 Detection rates for gastric cancer and high-grade intraepithelial neoplasia using TUS-OCCA (data analyzed according to location)  

| Location of lesions | Patients (n) | Detection rates of TUS-OCCA |
|---------------------|-------------|-----------------------------|
| Antrum              | 92          | 87/92 (95%)                 |
| Angle               | 73          | 70/73 (96%)                 |
| Body                | 39          | 38/39 (97%)                 |
| Fundus              | 8           | 5/8 (63%)                   |
| Cardia              | 76          | 70/76 (92%)                 |
| Total               | 288         | 270/288 (94%)               |

TUS-OCCA, transabdominal ultrasound after oral administration of an echoic cellulose-based gastric ultrasound contrast agent.

Table 3 Results of T staging using TUS-OCCA as compared with the pathological findings (by case)  

| Pathology | TUS-OCCA | Accuracy |
|-----------|----------|----------|
|           | T1a      | T1b      | T2      | T3      | T4      |
| T1a       | 10       | 6        | 0       | 0       | 0       |
| T1b       | 2        | 14       | 4       | 0       | 0       |
| T2        | 0        | 4        | 54      | 18      | 0       |
| T3        | 0        | 0        | 12      | 104     | 6       |
| T4        | 0        | 0        | 0       | 8       | 22      |

TUS-OCCA, transabdominal ultrasound after oral administration of an echoic cellulose-based ultrasound contrast agent. The overall accuracy of TUS-OCCA for T-staging was 77.3 % (204/264)
angle, and cardia) and antrum, rather than the gastric fundus [25, 26].

The echogenicity of lesions is another important influential factor. In our experience, the detection rates of TUS-OCCA for gastric polyps, which usually present with a mid to high echo, are low; the detection rates of TUS-OCCA for gastric cancer, which usually presents as hypoechoic thickening of the gastric wall, are high.

The most important reason why TUS-OCCA is currently performed and continues to be investigated is that...

Fig. 3 Early gastric cancer. a Examination involving transabdominal ultrasound scans after oral administration of an echoic cellulose-based gastric ultrasound contrast agent showing hypoechoic mucosal thickening of the gastric wall (black arrow). b Endoscopic ultrasound showing hypoechoic mucosal thickening of the gastric wall (white arrows). c and d Endoscopic resection of a lesion confirmed as early gastric cancer.

Fig. 4 Advanced gastric cancer. a and b Examination involving transabdominal ultrasound scans after oral administration of an echoic cellulose-based gastric ultrasound contrast agent showing hypoechoic thickening of the gastric wall with superficial ulceration (a, longitudinal section; b, cross section). c Gastroscopic examination showing the lesion. Arrow, pointing at the lesion.
the pathological regression of various gastric lesions has been better elucidated over the past 5 years. In defense of this position, the following factors should be considered: (1) the majority of gastric polyps are benign and are believed to possess no malignant potential [27–30]; (2) gastric precancerous lesions are usually composed of gastric mucosa with intestinal metaplasia or dysplasia presenting as hypoechoic mucosal thickening [31, 32]. Although the detection rate using TUS-OCCA for gastric polyps (which usually require no further treatment) is low, the detection rate for hypoechoic thickening of the gastric wall (which requires further treatment) is high.

One limitation of our study in common with others was that the gastric lesions of the enrolled patients were previously detected in gastroscopic examinations; this may have influenced the higher accuracy rates for the detection of the lesions, even though the examiner was blinded to the site, size, and endoscopic diagnosis of the lesions. Another limitation of the study is that it lacked negative controls, which also limited its accuracy.

In our experience, the sensitivity and specificity of TUS-OCCA for gastric dysplasia and cancer were 90.8 and 96 %, respectively [6]. The majority of patients whose lesions were undetected using TUS-OCCA were obese, and were classified into Group U [6]. In our experience, about 70 % of the population would be classified into Group S and about 30 % would be classified into Group U. Although TUS-OCCA examination is not suggested by ultrasonic physicians for patients classified into Group U, many still want to simultaneously undergo TUS-OCCA for mass screening of gastric cancer when they undergo conventional transabdominal ultrasound examination for mass screening of abdominal cancer. Certainly, written informed consent should be obtained from patients after they have been advised regarding the limits and disadvantages of TUS-OCCA. We believe that with promotion of

**Fig. 5** Cellulose-based contrast agent may provide fewer gas artifacts than water. a Mural gas and gastric mucus adherence to the gastric wall was increased when the stomach was filled with water, which may influence observations of the gastric wall. b Mural gas and gastric mucus adherence to the gastric wall were reduced when the stomach was filled with cellulose-based contrast agent, as a result of its greater bulk and surface tension properties, which optimize gas displacement and interfere with mural gas adherence.

**Fig. 6** As compared with water, the uniformity of the mid to high echoic contrast agent may improve ultrasound visualization of hypoechoic gastric tumors. a Because the echo intensity of the tumor was similar to that of the gastric fluid floating above the cellulose-based contrast agent, visualization of the hypoechoic tumor was blurred and unclear. b The uniformity of the mid to high echoic contrast agent could improve ultrasound visualization of the hypoechoic gastric tumors. Arrow, pointing at the hypoechoic tumor.
the TUS-OCCA technique and training in its use, it could be used as an alternative mass screening tool for gastric cancers, especially in the Asian population (China, Japan, and Korea) where the incidence of the disease is high and the body habitus of the population is more suitable.

Conclusions

TUS-OCCA achieved a high detection rate for gastric cancers, especially in patients with a suitable body habitus whose cardio and pylorus could both be visualized using transabdominal ultrasound. TUS-OCCA could be used to assess the depth of gastric cancer invasion. Many more successive studies will be needed to fully evaluate the utility of TUS-OCCA.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

ZL, JTG, SPW, YZ, JL, LPH, SST, LMX, YH, SYS, and WDR contributed to the design of the study. ZL performed the TUS-OCCA examinations. ZL, JTG, SPW, YZ, JL, LPH, SST, LMX, YH, SYS, and WDR contributed to the acquisition and analysis of the data. ZL, JTG, SPW, and YZ were involved in drafting the manuscript. ZL, JL, LPH, SST, LMX, YH, SYS, and WDR revised the manuscript. All authors read and approved the final version of the manuscript.

Acknowledgments

We thank all the doctors and nurses in the Shengjing Hospital of China Medical University who provided help with this study. This work was supported by grants from the Science and Technology Department of Liaoning Province (No. 2013225079).

Author details

1. Ultrasound Department, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Shenyang, Liaoning Province 110004, People’s Republic of China.

2. Endoscopy Center, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, People’s Republic of China.

3. Surgical Department, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, People’s Republic of China.

Received: 22 July 2015 Accepted: 19 November 2015

Published online: 25 November 2015

References

1. Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008;9(3):279–87.

2. Nakajima S. Gastric cancer screening in Japan, now and tomorrow. Nihon Rinsho. 2012;70:88–93.

3. Lee KS, Oh DK, Han MA, Lee HY, Jun JK, Choi KS, et al. Gastric cancer screening in Korea: report on the national cancer screening program in 2008. Cancer Res Treat. 2011;43(2):83–8.

4. Liu Z, Guo J, Sun S, Ren W, Tang S, Xie L, et al. Evaluation of transabdominal ultrasound after oral administration of an echoic cellulose-based gastric ultrasound contrast agent for demonstrating small gastric subepithelial masses. Abdom Imaging. 2014;39(2):424–31.

5. Liu Z, Guo J, Ren W, Sun S, Tang S, Xie L. A gastric calcifying fibrous pseudotumor detected by transabdominal ultrasound after oral administration of an echoic cellulose-based gastrointestinal ultrasound contrast agent. Ultrascal Med. 2014;35(2):181–3.

6. Liu Z, Guo J, Li J, Wang S, Tang S, Xie L, et al. Gastrointestinal lesions: demonstrated by transabdominal ultrasound after oral administration of an echoic cellulose-based gastric ultrasound contrast agent. Ultrascal Med. 2015; doich:dx.doi.org/10.1055/s-0034-1399719.

7. Li S, Huang P, Wang Z, Chen J, Xu H, Wang L, et al. Preoperative T staging of advanced gastric cancer using double contrast-enhanced ultrasound. Ultrascal Med. 2012;33:218–24.

8. Shi H, Yu XH, Guo XZ, Guo Y, Zhang H, Qian B, et al. Double contrast-enhanced two-dimensional and three-dimensional ultrasonography for evaluation of gastric lesions. World J Gastroenterol. 2012;18(31):4134–44.

9. Kypriais D, Fusaroli P, Artuso S, Poli F, Calletti G. Gastric ulcer penetration into the liver mimicking malignancy on endoscopic ultrasound. Endosc Ultrason. 2013;2(2):107–8.

10. Wei F, Huang P, Li S, Chen J, Zhang Y, Hong Y, et al. Enhancement patterns of gastric carcinoma on contrast-enhanced ultrasonography: relationship with clinicopathological features. PLoS One. 2013;8(9):e73050. doi:10.1371/journal.pone.0073050.

11. Rocha HL, Bueno FK, Faraco J, Asoel MS, Araki OM, Nakao F, et al. Heterotopic pancreas complicated by pseudocyst in the gastric wall diagnosed by endoscopic ultrasound-guided fine needle aspiration. Endosc Ultrason. 2013;2(3):159–61.

12. Kwee RM, Kwee TC. The accuracy of endoscopic ultrasonography in differentiating mucosal from deeper gastric cancer. Am J Gastroenterol. 2006;101(3):1801–9.

13. Pech O, Günter E, El C. Endosonography of high-grade intra epithelial neoplasia/early cancer. Best Pract Res Clin Gastroenterol. 2009;23(3):639–47.

14. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.

15. Secano-Mato D, Aragón N, Ferreras E, García-Pérez J, Cervantes-Amat M, Fernández-Navarro P, et al. Trends in oral cavity, pharyngeal, oesophageal and gastric cancer mortality rates in Spain, 1952–2006: an age-period-cohort analysis. BMC Cancer. 2014;14:254. doi:10.1186/1471-2407-14-254.

16. Zhang L, Wu C, Pi Y, Zhu M, Zhang L, Chen S, et al. The survival and the long-term trends of patients with gastric cancer in Shanghai, China. BMC Cancer. 2014;14:300. doi:10.1186/1471-2407-14-300.

17. Hashimoto A, Akazawa K, Itobe Y, Miyashiro I, Kashi H, Hodera Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16(1):1–27.

18. Guo J, Liu Z, Sun S, Wang G, Ge N, Liu X, et al. Endosonography-assisted diagnosis and therapy of gastrointestinal submucosal tumors. Endosc Ultrason. 2013;2(3):125–33.

19. Salah W, Faigel DO. When to puncture, when not to puncture: Submucosal tumors. Endosc Ultrason. 2014;3(2):98–108.

20. Liu R, Adler DG. Duplication cysts: diagnosis, management, and the role of endoscopic ultrasonography. Endosc Ultrason. 2014;3(1):52–60.

21. Bruniati MS. Endoscopic ultrasound comes of age: mature, established, creative and here to stay! Endosc Ultrason. 2014;3(3):143–51.

22. Genta RM. Screening for gastric cancer: does it make sense? Aliment Pharmacol Ther. 2004;20 Suppl 2:42–7.

23. Fuentes Santos C, Steen B. Aspiration of barium contrast. Case Rep Endoscopy. 2014;2014:5882. doi:10.1155/2014/5882.

24. Mazoni G, Radice E, Baneggi E, Portu GB. Hydrosonography of the gastrointestinal tract. Am J Roentgenol. 2009;193(3):700–8.

25. ASGE Standards of Practice Committee, Sharaf RN, Shergill AK, Odze RD, Kirnsky ML, Fukami N, et al. Endoscopic mucosal tissue sampling. Gastrointest Endosc. 2013;78(2):216–24.

26. Dietrich CF, Jensen C. Endoscopic ultrasound-guided sampling in gastroenterology: European society of gastrointestinal endoscopy technical guidelines. Endosc Ultrason. 2013;2(11):177–22.

27. Carmack SW, Genta RM, Schuler CM, Sabourian MH. The current spectrum of gastric polyps: a 1-year national study of over 120,000 patients. Am J Gastroenterol. 2005;104(6):1524–32.

28. Hongo M, Fujimoto K. Gastric Polyps Study Group. Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan. J Gastroenterol. 2010;45(6):618–24.

29. Cao H, Wang B, Zhang Z, Zhang H, Qu R. Distribution trends of gastric polyps: an endoscopy database analysis of 24121 northern Chinese patients. J Gastroenterol Hepatol. 2011;27(7):1175–80.

30. Shab YH, Ruggier M, Graham DY, Genta RM. Management of gastrointestinal polyps: an endoscopy-based approach. Clin Gastroenterol Hepatol. 2013;11(11):1374–84.

31. Díaz-Ríbeiro A, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Saarest M, O’Connor A, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endosc. 2012(44(1)):74–94.

32. Hirot A, Zuckerman MJ, Adler DG, Davila RE, Egan J, Leighton JA, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc. 2006;63(4):570–80.